Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Exploratory Study of Sequential Triple Therapy (Temozolomide/Anlotinib/Bemarituzumab) in Combination With Concurrent Radiotherapy With Temozolomide and Anlotinib for the Maintenance Treatment of Diffuse Midline Gliomas in Children

NCT07020052 is registered in ClinicalTrials.gov with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology as lead sponsor.

NCT NCT07020052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07020052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Exploratory Study of Sequential Triple Therapy (Temozolomide/Anlotinib/Bemarituzumab) in Combination With Concurrent Radiotherapy With Temozolomide and Anlotinib for the Maintenance Treatment of Diffuse Midline Gliomas in Children
Lead sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase
Observational
Overall status
Not yet recruiting
Start date
July 10, 2025
Completion date
July 30, 2030
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

maintenance treatment of diffuse midline gliomas in children